Literature DB >> 2524129

Leukopenia with neutropenia associated with teicoplanin therapy.

A Del Favero1, L Patoia, G Bucaneve, L Biscarini, F Menichetti.   

Abstract

The first case report of leukopenia with neutropenia due to the new glycopeptide antibiotic teicoplanin is described. The side effect occurred in a 73-year-old man hospitalized because of subacute bacterial endocarditis caused by Streptococcus faecalis. Leukopenia with neutropenia (white blood cells 2000/mm3, neutrophils 46%) developed after 20 days of teicoplanin therapy. After stopping teicoplanin white blood cell and neutrophil counts reverted to normal, but dropped again on rechallenge. A review of 1500 records of patients treated with teicoplanin alone or in combination with other drugs was also performed. Five cases were found in which leukopenia was possibly (four cases) or probably (one case) related to teicoplanin therapy. From these preliminary data the incidence of leukopenia related to teicoplanin seems to be low.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2524129     DOI: 10.1177/106002808902300109

Source DB:  PubMed          Journal:  DICP        ISSN: 1042-9611


  4 in total

Review 1.  A risk-benefit assessment of teicoplanin in the treatment of infections.

Authors:  F de Lalla; A Tramarin
Journal:  Drug Saf       Date:  1995-11       Impact factor: 5.606

2.  Teicoplanin-induced leucopenia with immediate resolution after administration of G-CSF.

Authors:  Peysh Patel; Jonathan Sandoe; Wazir Baig
Journal:  BMJ Case Rep       Date:  2012-08-13

Review 3.  [Evaluation of hematologic side effects of anti-infective therapy: agranulocytosis caused by beta-lactam antibiotics, vancomycin and amodiaquine].

Authors:  G Eich; K A Neftel
Journal:  Infection       Date:  1991       Impact factor: 3.553

4.  Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.

Authors:  W R Outman; C H Nightingale; K R Sweeney; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.